Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts

Executive Summary

Pertuzumab’s approval came almost a year after FDA and Genentech battled over the future of bevacizumab’s breast cancer claim at an unprecedented public hearing. While both oncologic agents were approved on the basis of a median progression-free survival benefit exceeding five months, the regulatory similarities end there.

Advertisement

Related Content

Neoadjuvant Surrogate Endpoint Is Tough Sell, But FDA Panel Says Perjeta Worth A Chance
Roche Oncology Turns In A Third Quarter To Rival The Good Old Days
Genentech’s Perjeta Clears FDA Despite Unresolved Manufacturing Issues
Genentech Thinks Pertuzumab Will Escape Avastin Problem, Despite Similarities
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim
Avastin Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
Avastin’s Breast Cancer Approval Followed CDER Rift On Efficacy
Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel